Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) have earned a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $49.3333.

A number of research analysts recently commented on MLYS shares. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. TD Cowen initiated coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st.

Mineralys Therapeutics News Summary

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Regulatory milestone remains on track: The company reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational treatment for hypertension, and said commercial launch preparations are progressing in anticipation of approval. Mineralys second-quarter results and corporate update
• Positive Sentiment: Financial flexibility improved: Management highlighted a strong cash position with funding expected to support operations into 2028. Strategic financing initiatives and the repurchase of the Tanabe royalty obligation also strengthen the long-term economics of lorundrostat by reducing a future royalty burden. Mineralys launch readiness and cash runway
• Positive Sentiment: New medical leadership: Mineralys appointed cardiovascular medicine executive Dr. Terry Ferguson as chief medical officer. He will oversee medical strategy and late-stage clinical activities ahead of the potential lorundrostat launch. Mineralys appoints chief medical officer
• Neutral Sentiment: Short-interest data offered little signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio, suggesting the data does not indicate meaningful short-selling pressure.
• Negative Sentiment: Quarterly loss missed expectations sharply: Mineralys reported a second-quarter loss of $2.85 per share, compared with the analyst consensus estimate of a $0.55 loss. The sizable variance may be weighing on the stock, although the company remains focused on its pre-commercial development and launch activities. Mineralys second-quarter earnings call transcript

Mineralys Therapeutics Stock Down 1.0%

MLYS stock opened at $27.05 on Thursday. Mineralys Therapeutics has a twelve month low of $12.59 and a twelve month high of $47.65. The company has a market cap of $2.23 billion, a PE ratio of -6.38 and a beta of 0.68. The business’s 50-day simple moving average is $26.42 and its 200 day simple moving average is $27.60.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.30). On average, equities research analysts anticipate that Mineralys Therapeutics will post -2.3 EPS for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In other news, CEO Jon Congleton sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $26.14, for a total value of $1,960,500.00. Following the sale, the chief executive officer directly owned 614,321 shares in the company, valued at approximately $16,058,350.94. This represents a 10.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $25.90, for a total value of $2,696,811.60. Following the completion of the transaction, the insider directly owned 38,400 shares of the company’s stock, valued at approximately $994,560. The trade was a 73.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 217,313 shares of company stock worth $5,624,488. 18.94% of the stock is currently owned by company insiders.

Institutional Trading of Mineralys Therapeutics

Large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Mineralys Therapeutics by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock valued at $271,000 after acquiring an additional 702 shares during the period. Navalign LLC acquired a new stake in shares of Mineralys Therapeutics during the 4th quarter worth about $33,000. Velan Capital Investment Management LP increased its position in shares of Mineralys Therapeutics by 0.6% during the 3rd quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock worth $6,659,000 after purchasing an additional 1,000 shares in the last quarter. Royal Bank of Canada lifted its holdings in Mineralys Therapeutics by 262.3% during the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after purchasing an additional 1,107 shares during the last quarter. Finally, KBC Group NV bought a new position in Mineralys Therapeutics during the 1st quarter valued at about $33,000. 84.46% of the stock is currently owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.